| Literature DB >> 30531312 |
Margaret N Kosek1, Pablo Peñataro-Yori2, Maribel Paredes-Olortegui2, John Lefante3, Cesar Ramal-Asayag2, Marcelo Zamora-Babilonia2, Graciela Meza-Sanchez2, Richard A Oberhelman3.
Abstract
Probiotics are increasingly used for diarrhea, but studies under the Food and Drug Administration and Investigational New Drug program are few. We conducted a phase-one placebo-controlled study of Lactobacillus reuteri DSM 17938 under Investigational New Drug program in 60 children 2-5 years of age (41 L. reuteri, 19 placebos) in a resource-constrained community in Peru. No differences in objective data on adverse events were noted, although some differences based on subjective parental reports for fever and diarrhea were seen.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30531312 PMCID: PMC6557701 DOI: 10.1097/INF.0000000000002267
Source DB: PubMed Journal: Pediatr Infect Dis J ISSN: 0891-3668 Impact factor: 2.129